Neuralstem's Cell Therapy Is Working, And This Is Just The Beginning

Back in February 2014, we wrote an article for Seeking-Alpha reviewing the recently published Phase 1 data on Neuralstem's (NYSEMKT:CUR) NSI-566 for the treatment of Amyotrophic Lateral Sclerosis ("ALS"). This article is now exclusive to PRO subscribers, but we can point investors to the full peer-reviewed paper published in the Annals of Neurology (Feldman et al, 2014) for a comprehensive review of the Phase 1 study. Below we summarize some of the conclusions from that paper, and then point to significant anecdotal evidence that the current Phase 2 study is not only proceeding well, but succeeding in its primary goal of demonstrating safety and efficacy of NSI-566 for the treatment of ALS.

Professional Idea Filters to zero-in based on industry, market cap and more

PRO Top long ideas returned 21.7% in 2016**

"As a PRO member, we get uniquely valuable perspective that go beyond our quantiative analysis... We rely on PRO to get beyond the numbers quickly and add much needed perspective. It keeps me ahead of the next big thing. - Mark Choate, Malaga Cove Capital"

Mark Choate, Malaga Cove Capital

"Contributors (writers and commentators), often have a long history in the secuirities they opine on and some are clearly well positioned industry participants with detailed industry views that can help provide color on where the skeletons are buried in a particular secuirity and/or industry."

Jim Roumell, Roumell Asset Management

You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details

** The 21.7% return noted above was calculated as follows. For every top long idea published, the performance is on price at the close prior to publication of the article and price at December 31 2016 and was taken in equal weighting across every top idea published in 2016. Dividends are not included (except in rare cases where we may adjust starting price for an outsized dividend depending on its timing). We close positions where a merger deal has happened either at the takeover price (if in cash) or at the final price traded (if in stock). The 21.7% return does not include the effect of any management fees, brokerage commissions or other expenses which might be incurred by an investor. The 21.7% return is not audited data. The 21.7% return does not include reinvestment of dividends.

Past performance is no guaranty of future results. Investment ideas presented in the future on SA PRO Top ideas might result in losses or less attractive returns.

SA Pro Top Long ideas include small-cap, mid-cap and large-cap stocks, whereas the S&P 500 is populated by larger capitalization stocks.